Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.59 |
| ▸ | NOS3 | P29474 | 5/20 | 0.53 |
| ▸ | NOS2 | P35228 | 4/20 | 0.53 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400159 | 0.98 | NOS1 (0.61) | NOS1NOS3NOS2QRFPR | |
| SCHEMBL4397463 | 0.84 | NOS1 (0.58) | NOS1NOS3NOS2QRFPR | |
| Hydrochloric Acid SCHEMBL4406092 | 0.82 | NOS1 (0.56) | NOS1NOS3NOS2QRFPR | |
| SCHEMBL4395133 | 0.82 | NOS1 (0.59) | NOS1NOS3NOS2 | |
| Iodide SCHEMBL4401426 | 0.81 | NOS1 (0.72) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL4400405 | 0.81 | NOS1 (0.58) | NOS1NOS3NOS2 | |
| SCHEMBL4395153 | 0.80 | NOS1 (0.61) | NOS1NOS3NOS2QRFPR | |
| SCHEMBL4409794 | 0.79 | NOS1 (0.74) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL4402692 | 0.79 | NOS1 (0.59) | NOS1NOS3NOS2QRFPR | |
| Iodide SCHEMBL9053048 | 0.77 | NOS1 (0.96) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576241-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2009-08-18 | — | — | US | disclosed |
| US-7473779-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20060084667-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2006-04-20 | — | — | US | disclosed |
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
| US-20060084667-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | ADM2, NUP155, ABCG2 | NOS1 247/4885NOS3 100/4885NOS2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.